Vertex Pharmaceuticals (VRTX) Restructuring Costs (2009 - 2018)

Vertex Pharmaceuticals' Restructuring Costs history runs 10 years deep, the most recent figure standing at -$4000.0 for Q4 2018.

• On a quarterly basis, Restructuring Costs fell 101.03% year-over-year to -$4000.0 in Q4 2018; TTM through Sep 2019 was -$4000.0, a 100.7% decrease from a year earlier, with the FY2018 full-year figure at -$184000.0, down 101.29% from the prior year.
• Restructuring Costs declined to -$4000.0 in Q4 2018 per VRTX's latest filing, from $174000.0 in the prior quarter.
• Across five years, Restructuring Costs topped out at $40.8 million in Q3 2014 and bottomed at -$3.3 million in Q1 2015.
• The 5-year median for Restructuring Costs is $365000.0 (2016), against an average of $3.4 million.
• Across the five-year window, Restructuring Costs soared 15766.67% in 2014 and slumped 152.88% in 2015, its largest moves.
• Year by year, Restructuring Costs stood at $4.2 million in 2014, then plunged by 63.4% to $1.5 million in 2015, then slumped by 85.3% to $224000.0 in 2016, then jumped by 72.77% to $387000.0 in 2017, then sank by 101.03% to -$4000.0 in 2018.
• Per Business Quant, the three latest VRTX Restructuring Costs figures stand at -$4000.0 (Q4 2018), $174000.0 (Q3 2018), and -$62000.0 (Q2 2018).